MAX-10181 Given Orally to Patients With Advanced Solid Tumor

Summary

This is a multi-center, first-in-human, non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in patients with advanced solid tumor.

Timeline

Start

2020-02-11

Primary completion

2022-10-01

Completion

2022-11-01

Drugs

Indications